As a tyrosine kinase inhibitor, sunitinib activates p62-dependent selective autophagy, thus inhibiting tumor PDL1 expression and facilitating anticancer immunity in metastatic breast cancer [135]. The gene discussed is SQSTM1; the disease is neoplasm.